Clinical Trials Browser

HER2 Positive Breast Cancer

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

68 enrolled

Breast

Breast Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

113 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05378464 2026-04-01

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Phase 1 Recruiting

28 enrolled

Breast

Breast Neoplasms

NCT05143970 2026-03-20

CHANCES

Phase 1 Recruiting

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05187182 2026-03-18

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Phase 1 Recruiting

42 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04253561 2026-03-16

IPATHER

Phase 1 Completed

17 enrolled

Breast

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

200 enrolled

Breast

Breast Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 1 Active not recruiting

123 enrolled

Other solid neoplasm

Solid Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

198 enrolled

Breast

Breast Neoplasms

Clinical Trials

Panther

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

CHANCES

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

IPATHER

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread